IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 240 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,565,344 | -46.2% | 195,180 | -0.7% | 0.00% | -50.0% |
| Q1 2024 | $2,911,552 | +51.5% | 196,461 | -16.9% | 0.00% | +33.3% |
| Q4 2023 | $1,921,591 | +70.8% | 236,358 | -4.4% | 0.00% | +50.0% |
| Q3 2023 | $1,125,356 | -32.1% | 247,331 | +5.0% | 0.00% | 0.0% |
| Q2 2023 | $1,658,434 | +69.6% | 235,573 | +47.2% | 0.00% | +100.0% |
| Q1 2023 | $977,930 | -6.1% | 160,054 | -1.8% | 0.00% | -50.0% |
| Q4 2022 | $1,041,615 | -32.5% | 163,007 | +1.3% | 0.00% | -33.3% |
| Q3 2022 | $1,542,000 | -15.3% | 160,973 | -2.4% | 0.00% | 0.0% |
| Q2 2022 | $1,821,000 | -36.3% | 164,937 | -3.9% | 0.00% | -25.0% |
| Q1 2022 | $2,858,000 | -19.8% | 171,647 | -8.1% | 0.00% | 0.0% |
| Q4 2021 | $3,565,000 | -36.3% | 186,741 | -17.7% | 0.00% | -42.9% |
| Q3 2021 | $5,597,000 | -13.6% | 226,963 | -8.8% | 0.01% | -12.5% |
| Q2 2021 | $6,475,000 | -17.2% | 248,831 | +0.7% | 0.01% | -20.0% |
| Q1 2021 | $7,824,000 | -32.0% | 247,116 | -0.4% | 0.01% | -37.5% |
| Q4 2020 | $11,514,000 | +43.9% | 248,146 | +2.1% | 0.02% | +23.1% |
| Q3 2020 | $8,000,000 | +25.2% | 243,022 | +4.4% | 0.01% | +18.2% |
| Q2 2020 | $6,392,000 | +19.9% | 232,871 | +30.8% | 0.01% | 0.0% |
| Q1 2020 | $5,331,000 | +7.6% | 178,078 | -0.5% | 0.01% | +37.5% |
| Q4 2019 | $4,954,000 | +52.3% | 178,961 | +0.1% | 0.01% | +33.3% |
| Q3 2019 | $3,252,000 | -24.9% | 178,698 | +1.2% | 0.01% | -33.3% |
| Q2 2019 | $4,329,000 | +178.8% | 176,564 | +8.1% | 0.01% | +200.0% |
| Q1 2019 | $1,553,000 | +5.9% | 163,292 | -1.5% | 0.00% | 0.0% |
| Q4 2018 | $1,467,000 | +3.6% | 165,712 | +31.7% | 0.00% | 0.0% |
| Q3 2018 | $1,416,000 | -12.0% | 125,824 | +0.1% | 0.00% | 0.0% |
| Q2 2018 | $1,610,000 | -15.1% | 125,754 | +12.0% | 0.00% | -25.0% |
| Q1 2018 | $1,897,000 | +144.5% | 112,246 | +15.7% | 0.00% | +100.0% |
| Q4 2017 | $776,000 | +17.0% | 97,044 | +13.5% | 0.00% | +100.0% |
| Q3 2017 | $663,000 | -3.6% | 85,485 | -8.7% | 0.00% | 0.0% |
| Q2 2017 | $688,000 | – | 93,664 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 3,019,201 | $26,720,000 | 20.38% |
| Broadfin Capital, LLC | 5,951,153 | $52,668,000 | 6.92% |
| GREAT POINT PARTNERS LLC | 5,567,348 | $49,271,000 | 6.23% |
| Avoro Capital Advisors LLC | 10,261,039 | $90,810,000 | 5.43% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $19,367,000 | 5.00% |
| Prosight Management, LP | 1,062,500 | $9,403,000 | 4.85% |
| Perceptive Advisors | 12,241,111 | $108,333,000 | 4.12% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,850,000 | 3.21% |
| QVT Financial LP | 1,021,361 | $8,696,000 | 2.84% |
| Vivo Capital, LLC | 1,600,000 | $14,160,000 | 1.81% |